Celltech - Pipeline Highlights

• Key mid/late phase products

• CDP 870 Promising Phase II Pharmacia/Celltechanti-TNF? Ab fragment results in RA and Crohn’s

• Humicade™ Recruitment completed Celltechanti-TNF? Ab in Crohn’s Ph III studies

• PDE 4 inhibitor Ph II studies in Merck asthma and COPD

• BMS275291 Ph III in lung cancer; BMSselective MMP inhibitor Ph II in other cancers

• Exceptional pipeline includes large market opportunities

• Celltech retains substantial value in key products

Previous slide

Next slide

Back to first slide

View graphic version